Table 1 Association of GCDFP-15 expression with baseline clinico-pathological parameters

Total

602

363 (60.3%)

239 (39.7%)

-

HR (n = 576)

0.034^a

Negative

175

116 (66.3%)

59 (33.7%)

Positive

401

228 (56.9%)

173 (43.1%)

HER2 (n = 576)

0.035^a

Negative

478

299 (62.6%)

179 (37.4%)

Positive

116

60 (51.7%)

56 (48.3%)

Biological tumor types (n = 569)

0.001^b

HR+/HER2-

328

189 (57.6%)

139 (42.4%)

HR+/HER+

68

37 (54.4%)

31 (45.6%)

HR-/HER2+

43

19 (44.2%)

24 (55.8%)

HR-/HER2-

130

96 (73.8%)

34 (26.2%)

AR (n = 545)

<0.0001^a

Negative

238

180 (75.6%)

58 (24.4%)

Positive

307

149 (48.5%)

158 (51.5%)

Age (n = 602)

0.066^a

< 50 years

273

176 (64.5%)

97 (35.5%)

> = 50 years

329

187 (56.8%)

142 (43.2%)

Histological type (n = 602)

0.090^b

Ductal/others

554

340 (61.4%)

214 (38.6%)

Lobular

48

23 (47.9%)

25 (52.1%)

Grading (n = 601)

<0.0001^a

G1-2

463

261 (56.4%)

202 (43.6%)

G3

138

102 (73.9%)

36 (26.1%)

cT (n = 591)

0.181^a

cT1-2

395

230 (58.2%)

165 (41.8%)

cT3-4

196

126 (64.3%)

70 (35.7%)

cN (n = 583)

0.008^a

cN0

261

141 (54.0%)

120 (46.0%)

cN+

322

209 (64.9%)

113 (35.1%)